Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

Abstract

Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus.

Introduction

Herpesviridae persist — after primary infection usually in childhood or adolescence — lifelong in their hosts and can reactivate in situations of immune deficiency, like malignant diseases. Rates of reactivation depend on several factors such as underlying disease [1, 2], disease activity [3], antineoplastic therapy [1, 2], co-medication, comorbid conditions, and age [1]. Reactivation can lead to localized disease, as stomatitis and genital ulcers in case of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) or herpes zoster in case of varicella zoster virus (VZV), but also to viral dissemination, cerebral or visceral disease contributing to significant morbidity and mortality [4, 5]. Different strategies to prevent symptomatic reactivation are possible: risk-adapted pharmacological prophylaxis, suppressive therapy (after severe complication or in case of multiple reactivations), and pre-emptive treatment (in asymptomatic patients after virus detection by screening methods) [6]. Additionally, to prevent herpes zoster vaccination has become available as general prophylaxis and is recommended for adults aged 50 years or older. The European Medicines Agency (EMA) has recently expanded the approval to adults ≥ 18 years who are at increased risk of herpes zoster.

Quantity of data as well as systematic reviews and present guidelines describe risks of herpesvirus reactivation and prophylactic interventions in patients undergoing allogeneic [6, 7] or autologous [8] hematopoietic stem cell transplantation (HSCT). However, systematic analyses and trials of herpesvirus reactivation in patients with solid tumours or hematologic malignancies who are not candidates for HSCT are limited [4] but increasing, acknowledging the variable risks in the era of new therapeutics. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematologic malignancies not undergoing allogeneic or autologous HSCT or cellular therapy (CAR T cell therapy) and constitutes an update of the guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) of 2015 “Antiviral prophylaxis in patients with solid tumours and hematological malignancies” [9] focusing on HSV-1, HSV-2, and VZV.

Methods

In 2015, recommendations for antiviral prophylaxis in patients with solid tumours and hematologic malignancies were published by the AGIHO [9]. Meanwhile, many new antineoplastic drugs have been approved. Drug combinations are used frequently for the treatment of patients with solid tumours and hematological malignancies. Moreover, vaccination has become available as preventive strategy for VZV reactivation. Therefore, an update of the recommendations was deemed necessary. This article represents the update regarding HSV-1, HSV-2, and VZV; recommendations regarding Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus type 6 (HHV-6) will be updated in a separate article.

An expert panel of twelve oncologists, infectious disease specialists, and microbiologists — all members of the AGIHO — conducted independent literature search of the PubMed and Medline databases, using the following search terms: herpes simplex cancer prophylaxis, herpes simplex cancer therapy, varicella zoster cancer prophylaxis, and varicella zoster cancer therapy, restricted to adult patients. The literature search extended initially from January 2013 to August 2020, and was updated on 30 April 2021. Articles in English and German were included. References and other literature published before 2013 were included in the assessment process if relevant. Abstracts presented at the annual meetings of the DGHO, the European Hematology Association (EHA), the European Society of Medical Oncology (ESMO), the American Society of Hematology (ASH), and the American Society of Oncology (ASCO) from 2013 to 2020 were included if relevant. The expert panel weighed the search results in a stepwise consensus process consisting of personal meetings, video conferences, and e-mail discussions. Strength of recommendation (SoR) and quality of evidence (QoE) were graded according to the criteria applied by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) [10] (Table 1). A formal consensus meeting took place at the general assembly of the AGIHO, as video conference on 6 October 2020, to which all members of the AGIHO were invited. Recommendations were finally approved by discussion and online voting among the participating experts. This guideline provides an evaluation of present evidence (which is sparse in some fields) and the experts’ consensus interpretation. The recommendations intend to assist physicians in decisions on individual patients [8].

Table 1.

Strength of recommendation (SoR) and quality of evidence (QoE) as proposed by the European Society of Clinical Microbiology and Infectious Diseases [10]

Category	Definition
Strength of recommendation (SoR)
A	Strongly supports a recommendation for use
B	Moderately supports a recommendation for use
C	Marginally supports a recommendation for use
D	Supports a recommendation against use
Quality of evidence (QoE)—level
I	Evidence from at least one properly designed randomized, controlled trial
II	Evidence from at least one well-designed clinical trial, without randomization; from cohort- or case-controlled analytic studies (preferably from > 1 center); from multiple time series; or from dramatic results of uncontrolled experiments
III	Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies, or reports of expert committees
Quality of evidence (QoE) – index, for level II
r	Meta-analysis or systematic review of randomized controlled trials
t	Transferred evidence, that is, results from different patient cohorts, or similar immune-status situation
h	Comparator group is a historical control
u	Uncontrolled trial
a	Published abstract (presented at an international symposium or meeting)

Manifestations of HSV-1, HSV-2, and VZV

After primary infection, herpesviridae establish latency in sensory neural ganglia [11] (Table 2). Reactivation can occur by several triggers in the healthy population, but particularly in situations with reduced cell-mediated immunity [12]. Risk of symptomatic reactivation increases with intensity and duration of functional T cell suppression [4, 11].

Table 2.

Neurotrophic latency and forms of reactivation of herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV)

	HSV-1	HSV-2	VZV
Neurotrophic latency	Ganglion trigeminale, ganglion sacrale	Ganglion sacrale, Ganglion trigeminale	Cranial nerve ganglia, dorsal root ganglia
Reactivation	Asymptomatic viral shedding Herpes labialis Stomatitisa) Herpes genitalis Oesophagitis a) Hepatitis a) Colitis a) Pneumonitis a) Encephalitis Keratitis	Asymptomatic viral shedding Herpes genitalis Hepatitis a) Meningitis Encephalitis	Herpes zoster b) Disseminated herpes zoster a) Hepatitis a) Pancreatitis a) Pneumonitis a) Meningoencephalitis Cerebral vasculopathy Keratitis, uveitis, retinitis

^aIn immunocompromised patients.

^bIncluding atypical herpes zoster and zoster sine herpete (often presenting as visceral zoster).

Primary infection with HSV-1 occurs mainly in the oropharyngeal mucosa, but is unrecognized or asymptomatic in more than 80% of individuals [13, 14]. On the contrary, primary infection can be severe, manifesting as encephalitis, particularly in the immunocompromised individual. Although seroprevalence of HSV-1 reaches 90% in the general population by the age of 50 years [14, 15], only about one-third will suffer from symptomatic reactivation during lifetime [14]. Symptomatic reactivation typically occurs as herpes labialis (“coldsores”), but in the immunocompromised person, herpes stomatitis is often seen [12] (Table 2). Life-threatening reactivations are HSV encephalitis, HSV pneumonitis, and rarely other visceral manifestations [5, 16–18] (Table 2). Besides, HSV-1 is increasingly found in genital herpes [19] (Table 2). HSV-1 can also be detected in oral swabs in asymptomatic or oligosymptomatic individuals [14, 20].

Acquisition of HSV-2 results in infection at genital, perigenital, or anal skin sites, with seeding to sacral ganglia [21]. Occurrence in the oropharyngeal mucosa is less frequent in HSV-2. Severe primary manifestations are meningitis or other organ disease, mainly at very young age or in the immunocompromised. Seroprevalence shows considerable variation in different populations and ranges from 15 to 25% in industrialized countries [22]. Symptomatic reactivations mostly lead to genital ulcerous lesions and occur frequently [19]. Asymptomatic viral shedding is also common [23]. Severe manifestations are similar to HSV-1 (Table 2).

Primary infection with VZV in the naïve population results in varicella disease (“chickenpox”). Besides the characteristic skin lesions of macules, which progress to papules and then vesicles, systemic symptoms, like fever, may be present and are more pronounced in adolescents or adults compared to children [11]. Primary infection with VZV can affect organs and be life-threatening if it occurs in the immunocompromised individual. VZV establishes latency in sensory neurons and commonly reactivates as herpes zoster (“shingles”) in the elderly (≥ 50 years old), due to waning T cell immunity [11, 24, 25] (Table 2). While the incidence rate of herpes zoster in the population is 3.2 cases per 1000 person-years [26], it increases with age to 9.1 per 1000 person-years among persons 50 years of age or older [27]. Likewise, other conditions of T cell suppression may lead to herpes zoster in the younger population [24]. The incidence rate of herpes zoster is reported to be between 12 per 1000 person-years in individuals with solid tumours receiving immunosuppressive chemotherapy and 31 per 1000 person-years in patients with hematological malignancies receiving treatment [28, 29]. Typical herpes zoster appears as vesicular lesions in the distribution of dermatomes, accompanied by neuropathic pain [11], which can become chronic, leading to post-herpetic neuralgia in 15% [24]. Herpes zoster affecting the cranial nerves V (zoster ophthalmicus) or VII/VIII (zoster oticus or Ramsay Hunt syndrome) can be followed by longterm visual or hearing dysfunction. Further manifestations of reactivation in immunocompromised people are disseminated herpes zoster, meningoencephalitis, cerebral vasculopathy, pneumonitis, hepatitis, pancreatitis, or visceral zoster, that might be misdiagnosed as acute abdomen [11, 24, 30–32] (Table 2). Because VZV is highly contagious, > 90% of people have become infected before adolescence prior to widespread implementation of vaccination [24]. However, since vaccination against varicella during early childhood with a live attenuated varicella virus (vOka) has become universal practice in Germany in 2004 like in several countries [24, 25], the younger generation will not have experienced varicella disease, but the majority will have been vaccinated. Reactivation of the vaccine-type VZV (vOka) has been seen sporadically [24].

Studies on prophylactic strategies used different definitions of viral manifestation [33, 34] and focused on different endpoints: clinical manifestations (without virological confirmation) or clinical manifestations with virological findings or virus detection. Mortality is only reported in few studies. Whereas the terms disease, infection, and reactivation are not used consistently throughout literature, we will nominate primary manifestations as either infection (asymptomatic) or disease (symptomatic). Primary manifestations rarely occur during cancer treatment. By contrast, reactivations are frequent in cancer patients, particularly while on tumour treatment [35] and can be asymptomatic (viral shedding) or symptomatic, thus to be named here as disease by reactivation (clinical reactivation) (Table 2). In the immunocompromised patient, the clinical picture may be severe [5, 11, 21, 36] contributing to morbidity and mortality (Table 2). Risk-dependent prophylactic strategies are warranted to reduce the rate of clinical reactivation (e.g. stomatitis, herpes zoster, fever), complications (e.g. dissemination, post-herpetic neuralgia) and mortality. These are summarized in this guideline.

Diagnostics

Serology

Serology testing for HSV-1, HSV-2, and VZV is useful to ascertain prior infection in patients with acute leukaemia undergoing intensive chemotherapy and therefore identify patients at risk of reactivation (BIII) [11, 37] (Tables 3 and 4). However, seroprevalence of HSV-1 and VZV is about 90% for adults [14, 24], and thus, the majority of patients will have to be considered at risk of reactivation. Therefore, a universal prophylactic strategy for all patients with indication for prophylaxis of HSV-1 or VZV can be an alternative approach.

Table 3.

Recommendations for diagnostics of herpes simplex virus (HSV — if not otherwise specified referring to HSV-1 and HSV-2). Yield of all tests for virus detection might be influenced by whether the patient is receiving antiviral prophylaxis or not

Clinical situation	Intention	Diagnostic strategy	SoR	QoE	Comments	Reference
Patients at risk of HSV reactivation (patients with acute leukaemia planned for intensive therapy or other specified patient group)	Diagnosis of prior exposure, to decide about prophylaxis a)	HSV serology (IgG)	B	III	(see text)	[11, 37]
Patients with suspicion of HSV disease	To diagnose HSV disease	HSV serology (IgM, serial IgG)	D	III	Low sensitivity, time delay	[11]
	To diagnose HSV disease	qPCR for HSV vs. viral culture (mucosal swab, BW, BAL)	A	IItu	qPCR with higher sensitivity, reliability, speed	[39, 47, 48]
Patients with stomatitis after (radio-) chemotherapy	To diagnose HSV stomatitis	qPCR for HSV-1 (oral swab)	C	IIu		[14, 20, 43]
Patients with clinical diagnosis of herpes genitalis	To diagnose HSV	qPCR for HSV (genital or perianal swab, preferably vesicle content)	A	III	For differential diagnosis	[19, 44]
Patients suspected for herpes encephalitis	To diagnose HSV encephalitis	qPCR for HSV (CSF)	A	IItu	No exclusion by negative result, particularly if therapy has already started	[42, 49]
	To diagnose HSV encephalitis	HSV IgG (CSF/serum)	C	III	Additionally	[11, 49]
Patients suspected for herpes pneumonitis	To diagnose HSV pneumonitis	qPCR (BW, BAL)	A	IIu	HSV DNA may also stem from oropharyngeal sites (see text)	[48, 50]
Patients suspected for other organ HSV disease	To diagnose HSV visceral disease	qPCR for HSV (organ biopsy)	A	IItu	No exclusion by negative result, particularly if therapy has already started	[48]
Asymptomatic patients at risk for HSV reactivation	To screen for viral replication	qPCR for HSV-1 (mucosal swab)	D	I	Asymptomatic viral shedding; pre-emptive treatment not recommended	[11, 51]

BAL bronchoalveolar lavage, BW bronchial wash, CSF cerebrospinal fluid, QoE quality of evidence, qPCR quantitative polymerase chain reaction, SoR strength of recommendation.

^aWe consider a universal prophylactic strategy for all patients with indication for prophylaxis of HSV as equally appropriate, because seroprevalence of HSV-1 is about 90% for adults.

Table 4.

Recommendations for diagnostics of varicella zoster virus (VZV). Yield of all tests for virus detection might be influenced by whether the patient is receiving antiviral prophylaxis or not

Clinical situation	Intention	Diagnostic strategy	SoR	QoE	Comments	Reference
Patients at risk of VZV reactivation (patients with lymphoma or multiple myeloma or other specified patient group)	Diagnosis of prior exposure, to decide about prophylaxisa	VZV serology (IgG)	B	III
Patients with suspicion of VZV disease	To diagnose VZV disease	VZV serology (IgM, serial IgG)	D	III	Low sensitivity, time delay	[40, 52]
	To diagnose VZV disease	qPCR for VZV versus DFA or viral culture (skin swab, vesicle content)	A	IItu	qPCR with higher sensitivity, reliability; qPCR applicable on varying specimen	[41, 52]
Patients with typical segmental zoster lesion	To diagnose VZV	qPCR for VZV (skin swab)	C	III	Usually diagnosis on clinical grounds; for differential-diagnosis to HSV	[52]
Patients with atypical zoster lesion	To diagnose herpes zoster	qPCR for VZV (skin swab)	A	III		[52]
	To diagnose herpes zoster	qPCR for VZV (saliva)	B	II	Saliva more sensitive than blood	[40, 45]
	To diagnose herpes zoster	qPCR for VZV (blood)	C	II		[40, 45]
Patients with suspected zoster sine herpete	To diagnose VZV disease	qPCR for VZV (blood)	A	II	For rapid diagnosis	[40, 45, 52]
	To diagnose VZV disease	qPCR for VZV (saliva)	B	II		[40, 45]
Patients with suspected disseminated zoster	To diagnose VZV disease	qPCR for VZV (blood)	A	III	Not necessary if clinical diagnosis is obvious	[52]
Patients with zoster ophthalmicus	To diagnose ocular involvement	qPCR for VZV (affected superficial structure of the eye)	A	III	Ophthalmological examination recommended and often sufficient for diagnosis	[52]
Patients suspected for VZV encephalitis	To diagnose VZV encephalitis	qPCR for VZV (CSF)	A	II	No exclusion by negative result, particularly if therapy has already started	[49, 52, 53]
	To diagnose VZV	VZV IgG (CSF/serum)	C	III	Alternative in cerebral vasculopathy	[40, 49, 52]
	To diagnose VZV	qPCR for VZV (blood)	C	II		[53]
Patients suspected for VZV pneumonitis	To diagnose VZV pneumonitis	qPCR for VZV (BAL)	A	IIu	No exclusion by negative result, particularly if therapy has already started	[54]
	To diagnose VZV	qPCR for VZV (blood)	B	IIu		[54]
Patients suspected for other organ VZV disease	To diagnose VZV visceral disease	qPCR for VZV (organ biopsy)	A	III	No exclusion by negative result, particularly if therapy has already started	[11]
	To diagnose VZV	qPCR for VZV(blood)	A	III	No exclusion by negative result, particularly if therapy has already started	[52, 55]
Asymptomatic patients at risk for VZV reactivation	To screen for viral replication	qPCR for VZV (blood)	D	III	Pre-emptive treatment not recommended	[11]

BAL bronchoalveolar lavage, CSF cerebrospinal fluid, DFA direct fluorescence antibody, HSV herpes simplex virus, IgG immunoglobulin G, QoE quality of evidence, qPCR quantitative polymerase chain reaction, SoR strength of recommendation, VZV varicella zoster virus.

^aWe consider a universal prophylactic strategy for all patients with indication for prophylaxis of VZV as equally appropriate, because seroprevalence of VZV is about 90% for adults.

Serology testing (IgM or serial IgG) is not recommended to diagnose primary infection or reactivation of HSV or VZV due to low sensitivity [11], possible cross-reaction [38], and time delay (DIII) (Tables 3 and 4).

Virus detection

Quantitative polymerase chain reaction (qPCR) is a specific and sensitive technique for the detection of HSV-1, HSV-2 and VZV DNA. It is more reliable than direct virus antigen detection and viral culture, and also faster [11, 19, 39–41]. Moreover, the technique can be applied on different material, such as swabs (e.g. oral, genital, perianal, affected skin), vesicle content, blood, saliva, intraocular fluid, bronchial wash (BW), bronchoalveolar lavage (BAL), cerebrospinal fluid (CSF), and biopsies [38]. Thus, HSV/VZV qPCR is the method of choice to diagnose infection or reactivation (AII) (Tables 3 and 4).

Because HSV qPCR is as sensitive as detecting copy numbers of viral DNA at 10/sample [11] or 10/mL [42], the question arises whether a positive qPCR result of HSV necessarily means viral reactivation, or whether it represents an accidental finding of a small quantity of virus genome that probably always exists in latency [14]. Considering that HSV has a lytic effect on epithelial cells, the subclinical excretion of the virus is connected with microscopically visible or invisible ulcerations that remain unnoticed by the patient and the physician, a situation termed asymptomatic viral shedding, but still virus replication thus reactivation [14]. Therefore, it is not possible to define a threshold for diagnosis of HSV disease by reactivation at mucous or cutaneous sites [38, 43]. Disease by reactivation might be more likely with higher copy numbers of HSV DNA [20, 39]. By contrast, detection of HSV in CSF or biopsies is clinically significant [11]. Of note, negative PCR results cannot be interpreted as exclusion of diagnosis of HSV disease [44]. SoR and QoE for performing viral diagnostic for HSV-1 and HSV-2 in different clinical situations are listed in Table 3.

Diagnosis of primary VZV disease or VZV disease by reactivation can usually be made on clinical appearance as varicella and herpes zoster. Still, vesicle formation is a hallmark of VZV and HSV [45], and analysing VZV qPCR (swabs from affected skin is sufficient) and HSV qPCR (vesicle content is optimal) may be indicated to evaluate the causative agent, e.g. for assessment of transmission risk. VZV DNA in blood can be detected in varicella preceding the occurrence of rash by about ten days and persisting for two to three weeks. VZV DNA in blood is usually found at the onset of herpes zoster and for many weeks thereafter [40]. VZV DNA is also found in oropharynx, making saliva a suitable material for qPCR analysis of VZV [40, 46]. Therefore, VZV qPCR of blood or saliva can be helpful, particularly for atypical manifestations [24, 40] or when visceral disease is suspected in the absence of pathognomonic skin lesions [11]. Reported sensitivity of VZV DNA is 20–400 copies/mL depending on material [40]. SoR and QoE for performing viral diagnostics in different clinical situations with suspicion of VZV disease are listed in Table 4.

In asymptomatic patients at risk, there is no indication for screening and pre-emptive therapy of HSV-1, HSV-2, or VZV (DI; DIII) (Tables 3 and 4) [40]. Clinical suspicion should prompt immediate treatment as well as further diagnostics, including tissue biopsies, if appropriate [11] (Tables 3 and 4). Emphasis must be placed on clinical awareness of HSV or VZV reactivations in immunocompromised patients [13]. The absence of mucous or cutaneous lesions does not rule out the possibility of HSV and VZV disease since manifestations can be atypical.

Testing of resistance

Clinical reactivation of HSV or VZV in patients on antiviral prophylaxis does not imply routine resistance testing. Incompliance [56], omitted medication for other reasons [57] and reduced oral bioavailability [58] have to be considered. In contrast, testing for resistance has to be considered in patients on treatment with acyclovir, if no clinical improvement is seen after 5 days [38]. Whereas acyclovir resistance in VZV is a rarity, resistance in HSV is occasionally observed, necessitating a switch in antiviral treatment. Genotypic resistance testing is recommended and established in specialized laboratories.

Contribution of imaging techniques to diagnosis

Besides high awareness for clinical signs in populations at risk for HSV or VZV reactivation, imaging can be indicative in some manifestations: Cranial magnetic resonance imaging (MRI) is recommended for diagnosing encephalitis by HSV/VZV or cerebral vasculopathy in VZV and may be helpful in conjunction with other methods such as CSF PCR [49]. Pulmonary infiltration detected by chest computed tomography (CT) can indicate HSV or VZV pneumonitis, even though the appearance is not specific. On bronchoscopy, rendering a confident diagnosis of HSV or VZV pneumonitis is challenging, as many patients lack easily detectable herpetic lesions and findings might be nonspecific by superimposed coinfections [48].

Pharmacological prophylaxis

Acyclovir has for long been the mainstay for prophylaxis and treatment of HSV and VZV in immunocompromised patients [21].

A systematic review of oral herpetic viral disease of the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) showed that acyclovir orally is effective in preventing oral herpetic viral disease in patients with solid tumours or hematologic malignancies [34]. A most recent network meta-analysis compared different acyclovir regimens, evaluated in thirteen randomized controlled trials (RCT) on prevention of oral HSV disease in patients undergoing cancer treatment, including allogeneic or autologous HSCT: oral acyclovir 400 mg four times daily (QID) or oral acyclovir 400 mg twice daily (BID) or intravenous acyclovir 250 mg/m² TID were identified as most effective regimens to prevent oral HSV disease [36]. Since oral acyclovir 400 mg BID had an almost similar activity to oral acyclovir 400 mg QID, clinicians might prefer prescribing acyclovir 400 mg BID in most patients, particularly if renal function is a concern [36]. Valacyclovir, the L-valyl ester of acyclovir, has better oral bioavailability [36, 59]. Valacyclovir has been shown to be non-inferior to acyclovir in preventing HSV stomatitis in patients with acute leukaemia and intensive chemotherapy [60]. However, due to the limited number of reported trials, evidence is low and a network meta-analysis was not possible [36].

We recommend oral acyclovir 400 mg BID or 400 mg QID as prophylaxis of oral HSV disease (AIIr). Oral valacyclovir can be used alternatively (BI), but the best regimen (250 mg BID or 500 mg BID) has not yet been defined. For patients not tolerating oral medication, intravenous acyclovir 250 mg/m² TID is suitable (AIIr).

Long-term (6 to 12 months) oral administration of acyclovir, valacyclovir, or famciclovir, a well-absorbed prodrug of penciclovir, suppresses genital herpes in patients who have frequent recurrences (suppressive therapy). In a Cochrane meta-analysis of 26 trials in patients with at least four recurrences of genital herpes per year, 6950 participants were randomly assigned to either of the antiviral drugs or placebo [22]. Patients with immunosuppression were excluded in most of the trials [22]. Clinical recurrence of genital herpes was reduced with acyclovir (nine trials, pooled RR 0.48), valacyclovir (four trials, pooled RR 0.41), or famciclovir (two trials, pooled RR 0.57) [22]. The network meta-analysis was unable to determine which of the drugs was most effective [22, 23].

Thus, acyclovir, valacyclovir, and famciclovir have all shown to be effective in reducing the risk of recurrent genital herpes and of asymptomatic viral shedding. Acyclovir 400 mg BID has been tested and used widely (AI); valacyclovir 500 mg BID and famciclovir 500 mg BID are approved for this indication in immunocompromised patients (BIIt).

Acyclovir has been shown to reduce clinical VZV reactivation and to increase survival in patients undergoing HSCT, for whom the reactivation risk of VZV is as high as 50% [35]. Thus, antiviral prophylaxis with acyclovir has become standard of care in allogeneic and autologous HSCT recipients [4, 6, 8, 38, 61]. VZV reactivation risk in non-HSCT patients undergoing tumour treatment is also elevated, particularly in patients with lymphoma or multiple myeloma and best described for patients with multiple myeloma treated with proteasome-inhibitors, being up to 15% without antiviral prophylaxis [62]. VZV reactivation has remarkable influence on morbidity and quality of life. Therefore, antiviral prophylaxis is standard of care in these patients (for recommendations see below). However, no randomized controlled trials have been performed to find the most effective regimen (acyclovir has been used as 400 mg orally once daily, BID or TID most widely) or to compare acyclovir to valacyclovir or famciclovir.

We recommend oral acyclovir to reduce clinical VZV reactivation; dosages from 400 mg once daily to 400 mg TID have been shown to be effective (AII). Valacyclovir may also be effective by mechanism of action and due to transferred evidence, but has rarely been systematically tested [63, 64] (CIIu). For patients not tolerating oral medication, intravenous acyclovir is suitable, but evidence on the most appropriate dosage is lacking (BIIt).

Of note, all three nucleoside analogues (acyclovir, valacyclovir, famciclovir) require dose adjustment in patients with renal impairment.

Vaccination

VZV is the only human herpesvirus for which highly effective vaccines are available [24]. Since the introduction of a live attenuated varicella virus (vOKA) during childhood as primary prophylaxis against VZV, varicella disease and severe primary manifestations have decreased [25]. Still, the adult population nowadays almost universally experienced varicella disease and is therefore at risk of VZV reactivations, and incidences of VZV reactivation are rising. Recently, two different types of herpes zoster vaccines have been studied and approved [26]: The live-attenuated zoster vaccine Zostavax® is contraindicated in the immunocompromised [26]. The adjuvanted recombinant (non-live) subunit zoster vaccine Shingrix® has recently been approved for the prevention of herpes zoster and post-herpetic neuralgia for adults 50 years of age or older and for adults of any age at increased risk of herpes zoster. It has been studied in specific groups of patients with malignancies and shown to be safe [26, 65–68]. Nevertheless, immunogenicity [26, 66–68] and efficacy rates [26] seemed lower in patients while on tumour treatment than in the general elderly population: For instance, the incidence rate of herpes zoster was reduced from 66.2 per 1000 patient-years (placebo group) to 8.5 per 1000 patient-years (vaccine group) in 562 adults (≥ 18 years old) with hematologic malignancies in the zoster-39 trial [26], whereas in the ZOE-50 trial, herpes zoster incidence per 1000 patient-years was reduced from 9.1 (placebo group) to 0.3 (vaccine group) in more than 13.000 persons of at least 50 years of age [27]. Considering herpes zoster, vaccination with the recombinant zoster vaccine Shingrix® is recommended due to safety and immunogenicity, although data on clinical efficacy in certain malignancies are preliminary [66, 67, 69] and long-term protection rates are sparse. Until more data are available, particularly of comparative trials for vaccination versus pharmacological prophylaxis, it is suggested to apply acyclovir additionally in high risk patient groups (for recommendations see below). Around 30% of participants of the zoster-39 trial (i.e. patients with hematologic malignancies) received antiviral prophylaxis [26]. Nevertheless, it is anticipated that an increased use of the recombinant zoster vaccine Shingrix® in immunosuppressed patients would — if clinically shown effective — lead to a decreased use of pharmacological prophylaxis [70].

Patient groups

Patients with solid tumours

Compared to patients with hematologic malignancies with cumulative incidences of herpesvirus reactivations of up to 20% during the treatment phase and 5-year follow up, frequencies of herpesvirus reactivations are low (< 10%) in patients with solid tumours [4]. However, case reports and case series about severe complications by HSV or VZV have been described [5, 16–18]. This holds also true for patients treated with immune checkpoint inhibitors with or without chemotherapy [71, 72]. An intrinsically increased risk of clinical reactivation of HSV and VZV for immune checkpoint inhibitor therapy has not been described [73, 74]. But an increased risk has been seen with immunosuppressive treatments (corticosteroids and others), as used frequently in case of immune related adverse events [74]. Depending on dose and duration of immunosuppressive treatments antiviral prophylaxis may be warranted (Table 5).

Table 5.

Recommendations for pharmacological prophylaxis in patients with solid tumours

Clinical situation	Intention	Intervention	SoR	QoE	Comments	Reference
Patients with solid tumours and systemic therapy (in general; for specific risks see below)	To prevent HSV/VZV reactivation	Acyclovir	D	III	Low risk of reactivation
Patients with HNSCC, treated with radiochemotherapy	To prevent HSV stomatitis	Acyclovir	C	IIr		[34]
Patients with malignancies, taking corticosteroids in high doses long term (> 10 mg PEQ per day for 14 days or longer)	To prevent herpes zoster	Acyclovir	C	IIu	Persisting risk for several months after corticosteroid has been stopped (see text)	[77]

In patients with normal renal function, acyclovir is recommended with 400 mg orally BID (for more details refer to section “Pharmacological Prophylaxis).

HNSCC head and neck squamous cell carcinoma, HSV herpes simplex virus, PEQ prednisolone equivalent, QoE quality of evidence, SoR strength of recommendation, VZV varicella zoster virus.

The following patient groups need particular attention for HSV disease by reactivation (Table 5):

HSV stomatitis can occur and be severe in patients with head and neck cancer treated with radiochemotherapy [14]. Irradiation contributes to regional eradication of the cellular immune component that is responsible for controlling herpesvirus latency [75]. While no general recommendation on pharmacological prophylaxis can be given due to lack of evidence, acyclovir and valacyclovir have been shown to be preventive in an updated meta-analysis of 41 trials in different patient populations including patients with head and neck cancer treated with radiochemotherapy [34] (CIIr). Likewise encephalitis by HSV-1 has been described in patients with cranial irradiation of metastases [5, 17] and for malignant glioma [16]. In malignant glioma, concomitant treatment with dexamethasone and temozolomide increases the risk for HSV encephalitis [16]. To our knowledge, no trials have analysed the efficacy of pharmacological prophylaxis for this situation. Clinical awareness is important.

For disease by reactivation of VZV, specifically herpes zoster, the age and gender standardized incidence in relation to the general population is 4.8 for hematologic malignancies and 1.9 for solid tumours [28]. At 5 years, the cumulative incidence of herpes zoster is low at 5% in patients with solid tumours without antiviral prophylaxis [28]. Pharmacological prophylaxis to prevent disease by reactivation of VZV in patients with solid tumours is not generally indicated (DIII) (Table 5). Corticosteroids are used as supportive care in patients with solid tumours and hematologic malignancies. Dosages of 10 mg prednisolone equivalent (PEQ) or more per day for at least 14 days have been described to increase the risk of VZV reactivation [76]. In a large population-based cohort study of patients with different diseases (cancer, asthma, autoimmune diseases), the HR for herpes zoster was 2.37 compared to a matched population not taking corticosteroids [77]. The risk increased with concomitant immunosuppressive medication [77]. Therefore, even though no evidence from randomized trials exists, it might be reasonable to consider patients on corticosteroids, particularly with high doses long term (and/or if concomitantly treated or heavily pre-treated with immunosuppressive agents) for antiviral pharmacological prophylaxis (CIIu) (Table 5). Antiviral prophylaxis might be continued for up to 6 months after corticosteroids have been terminated [76].

Patients with acute leukaemia

The incidence of clinical reactivation of HSV in patients with acute leukaemia treated with intensive chemotherapy is high, affecting 37–68% of patients [14, 33]. In the majority, ulcerative stomatitis is seen, less commonly oesophagitis, pneumonitis, or genital lesions [60]. A systematic review and meta-analysis of antiviral prophylaxis in patients with hematologic malignancies performed by Yahav et al. [33] identified 22 trials, most of them referring to patients with allogeneic or autologous HSCT. Five trials included patients with intensive chemotherapy [33, 78–82]. Rates of symptomatic HSV reactivation were significantly lower with acyclovir compared to placebo (RR 0.10) [33]. There was no significant difference in overall mortality (RR 1.27) [33]. Even though the respective trials have all been performed more than twenty years ago (and particularly diagnostic methods as well as supportive care have evolved since then), our literature search could not reveal new trials to be considered, in line with the results of a very recent network meta-analysis by Aribi Al-Zoobaee et al. [36]. Considering the high risk of reactivation prophylactic acyclovir or valacyclovir should be applied in patients with acute leukaemia receiving intensive chemotherapy to reduce HSV stomatitis, and to reduce other HSV reactivations (BIIr) (Table 6). In patients with acute myeloid leukaemia antiviral prophylaxis should start with the initiation of intensive remission induction chemotherapy and be continued during the neutropenic phase. However, the duration varied from 28 to 100 days in clinical studies. No data specifically on consolidation therapy are available, but the incidence of oral HSV disease was much lower [20].

Table 6 .

Patients with acute leukaemia and myeloproliferative neoplasms

Clinical situation	Intention	Intervention	SoR	QoE	Comments	Reference
Patients with AML/high-risk MDS, planned for intensive therapy	To prevent HSV stomatitis and other clinical manifestations of HSV	Acyclovir, valacyclovira	B	IIr	For remission induction chemotherapy (see text)	[33, 36, 60, 79, 129]
	To prevent herpes zoster (and other clinical reactivation of VZV)	Acyclovir, valacyclovira	B	IIr	Particularly in patients with APL treated with arsenic trioxide (see text)	[33, 83]
Patients with ALL	To prevent HSV stomatitis and other clinical manifestations of HSV	Acyclovir	B	I	While on treatment	[78, 81]
	To prevent herpes zosterb	Acyclovir	B	III
Patients with MPN, treated with ruxolitinib	To reduce HSV disease	Acyclovir	C	IIu		[85–89]
	To prevent herpes zosterb	Acyclovir	B	IIru		[86–88]

In patients with normal renal function, acyclovir is recommended with 400 mg orally BID and valacyclovir is recommended with 500 mg orally BID (for more details refer to section “Pharmacological Prophylaxis).

AML acute myeloid leukaemia, ALL acute lymphoblastic leukaemia, APL acute promyelocytic leukaemia, HSV herpes simplex virus, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm, QoE quality of evidence, SoR strength of recommendation, VZV varicella zoster virus.

^aValacyclovir may be used as well, although trials are limited compared to acyclovir (see text).

^bData are mainly available for herpes zoster; evidence for other clinical reactivations of VZV is unclear.

Data on VZV reactivation rates are sparse, reported only in few trials [33, 80–82], but they seem low during the time of intensive chemotherapy. However, a very recent retrospective trial pointed at the significant risk of VZV reactivation in patients with acute promyelocytic leukaemia treated with arsenic trioxide: In 112 patients, disease by reactivation of VZV occurred in 17.5% of patients (including one patient with VZV encephalitis) without versus in 4.1% of patients with prophylaxis with acyclovir or valacyclovir (RR 0.24) [83]. Therefore, pharmacological prophylaxis for this patient group during the time of treatment till 6 months thereafter is recommended to reduce VZV disease (BIIr) (Table 6).

Only two older trials [78, 81] within the meta-analysis by Yahav et al. [33] reported about patients with acute lymphoblastic leukaemia. As these patients are exposed to even more intensive and prolonged chemotherapy protocols, including corticosteroids and sometimes anti-CD20 monoclonal antibodies (see below “Patients with lymphoma”) [84], antiviral prophylaxis to reduce reactivation of HSV and VZV is recommended for patients with acute lymphoblastic leukaemia while on treatment (BI) (Table 6).

Patients with myeloproliferative neoplasm

Infectious complications are main causes of morbidity and mortality in patients with myeloproliferative neoplasms, particularly in patients with myelofibrosis in advanced stage. Moreover, ruxolitinib, an inhibitor auf Janus kinases, modulates dendritic cell function resulting in impaired CD4 and CD8 T cell priming [85]. A systematic meta-analysis including five phase III trials on ruxolitinib revealed higher rates of herpes zoster among patients treated with ruxolitinib compared to control patients (OR 5.20) [86]. A retrospective study published as abstract showed similar results with an OR for VZV/HSV reactivation of 7.57 [87]. Results of registry data confirm the clinical relevance of clinical herpesvirus reactivations, mainly as herpes zoster [88, 89], but the benefit of antiviral prophylaxis has not been prospectively or retrospectively validated [89]. Recommendations and QoE are depicted in Table 6. While some authors [85, 89] favour the implementation of antiviral prophylaxis, high awareness by patient and doctor, thorough clinical examination and immediate treatment of reactivations, is generally warranted.

Patients with lymphoma

There are few data systematically analysing the risk of HSV and VZV reactivations in lymphoma patients. Moreover, to the best of our knowledge, results from recent randomized controlled trials on antiviral pharmacological prophylaxis have not been published. Two retrospective analyses from Korea evaluated the incidence of disease by herpesvirus reactivations in patients with lymphoma not receiving antiviral prophylaxis: Park et al. [90] found an incidence of herpesvirus disease of 10.7% in 270 patients with diffuse large B cell lymphoma (DLBCL) within 30 months of receiving immuno-chemotherapy with R-CHOP, of which 75.9% were caused by VZV, 20.7% by HSV, and 3.4% by CMV. Lee et al. [4] described the cumulative incidence of herpesvirus disease in 266 patients with non-Hodgkin lymphoma and Hodgkin’s lymphoma at 5 years being 20.16%. Again, reactivations of VZV were dominating with 93% [4]. Both trials [4, 90] identified a high cumulative dose of corticosteroids (cumulative PEQ dose ≥ 2500 mg/m² or 3000 mg/m² body surface area (BSA)) and a history of neutropenic fever as independent risk factors on multivariate analysis. Whereas these retrospective data only describe incidences of clinical reactivations of herpesviridae, introducing oral acyclovir (400 mg QID given from the start of therapy until four weeks after the last therapy cycle) together with cotrimoxazol (2 double strength doses twice a week) in addition to oral ciprofloxacin (500 mg BID) as anti-infective prophylaxis in the OPTIMAL > 60-trial significantly reduced grade 3/4 infections of all kind (from 28 to 18% per patient, p = 0.004) and treatment-related mortality (from 7 to 2%, p = 0.003) in elderly patients with DLBCL compared to a historical control [91]. Antiviral prophylaxis was also shown to reduce the risk of clinical reactivations of VZV and HSV in patients with indolent lymphomas treated with bendamustine ± anti-CD20 monoclonal antibody [92]. This evidence supports the use of pharmacological prophylaxis to reduce particularly VZV disease in non-Hodgkin lymphoma patients treated with (immuno-)chemotherapy (BIIu) (Table 7). Patients planned to receive > 2500 mg/m² BSA PEQ dose may especially benefit because risk of clinical reactivation of herpesvirus is high [4, 90], furthermore age > 60 years, advanced line of therapy, treatment with bendamustine, history of febrile neutropenia and history of HSV/VZV reactivation have been identified as risk factors.

Table 7.

Patients with lymphoma, chronic lymphocytic leukaemia and multiple myeloma

Clinical situation	Intention	Intervention	SoR	QoE	Comments	Reference
Patients with non-Hodgkin lymphoma, treated with immuno-chemotherapya	To reduce HSV/VZV disease	Acyclovir (valacyclovir)b	B	IIu	Persisting risk for several months after therapy (see text)	[4, 90, 92, 96, 130, 131]
	To reduce mortality	Acyclovir	C	IIah	Together with cotrimoxazol, in patients aged > 60 years	[91]
Patients with Hodgkin’s diseasea	To prevent herpes zoster	Acyclovir (valacyclovir) b)	C	III		[89]
Patients with CLL receiving immuno-chemotherapya	To reduce HSV/VZV disease	Acyclovir, (valacyclovir) b)	B	IIuh	Persisting risk for several months after therapy (see text)	[96–99]
Patients with CLL (and other Non- Hodgkin lymphoma) receiving BTK or BCL2 inhibitorsa	To prevent herpes zoster (to reduce VZV/HSV disease)	Acyclovir, (valacyclovir)b	C	IIu	Of benefit particularly in advanced lines of therapy	[103–107, 109, 110, 132]
Patients with CLL (and other Non-Hodgkin lymphoma) receiving idelalisib	to reduce HSV/VZV disease	acyclovir	B	III	High general risk of opportunistic infections, persisting for several months after therapy	[111, 113, 133]
Patients with MM, receiving bortezomib	To reduce VZV diseasec	Acyclovir, valacyclovir	A B	IIu IIu	d	[62, 64, 118–120, 125, 134–137]
Patient with MM receiving carfilzomib	To reduce VZV diseasec	e.g., acyclovir	A	IIu	d	[117, 119, 122, 127]
Patients with MM receiving ixazomib	To reduce VZV diseasec	e.g., acyclovir	A	IIh	d	[121, 123]
Patients with MM receiving lenalidomid	To reduce VZV diseasec	e.g. acyclovir	C	IIh	d	[121, 124]
Patients with MM receiving daratumumab	To reduce VZV diseasec	e.g. acyclovir	C	IIt	d	[116, 117, 128]
Patients with MM receiving elotuzumab	To reduce VZV diseasec	e.g. acyclovir	C	IIt	d	[117, 138]
Patients with MM receiving conventional-dose chemotherapye or other targeted agentsa	To reduce VZV diseasec	e.g. acyclovir	C	IIt	d	[117, 126] (see also above)

In patients with normal renal function, acyclovir is recommended with 400 mg orally BID or QID and valacyclovir is recommended with 500 mg orally BID (details are given in the section “Pharmacological Prophylaxis”).

CLL chronic lymphocytic leukaemia, MM multiple myeloma, BTK Bruton’s tyrosine kinase, BCL2 B-cell-lymphoma kinase 2, HSCT haematopoietic stem cell transplantation, HSV herpes simplex virus, QoE quality of evidence, SoR strength of recommendation, VZV varicella zoster virus.

^aIndividual risk assessment is recommended: The following risk factors have been described in patients with non-Hodgkin lymphoma or CLL: age > 60 years, concomitant treatment with high doses of corticosteroids (cumulative PEQ dose > 2500 mg/m² BSA), advanced line of therapy, type of therapy (bendamustine, maintenance by anti-CD20 monoclonal antibodies), history of febrile neutropenia, and history of HSV/VZV reactivation. The risk factors may also help in decision making for antiviral prophylaxis in patients with multiple myeloma.

^bValacyclovir has been used as well, but evidence is less clear.

^cVZV disease: data mainly refer to herpes zoster. Data on HSV disease are rarely reported (see text).

^dReactivation risk by a single agent is difficult to determine, because combinations were mainly used; prophylaxis in trials was frequently open (“might be considered or recommended”), and duration of prophylaxis has not been determined.

^eExcluding patients with multiple myeloma treated with high-dose chemotherapy and autologous HSCT. For those antiviral pharmacological prophylaxis is highly recommended: A IIt (to prevent HSV reactivation) and A IIu (to prevent VZV reactivation), details in [8]

There is no general recommendation for antiviral prophylaxis in patients with first line therapy of Hodgkin’s lymphoma (treated with ABVD or BEACOPPesc) according to study protocols [93, 94]. Still the risk of VZV reactivation may be elevated, partly due to corticosteroid exposure (Table 5). Decision about antiviral prophylaxis has to be made on individual case basis, referring to treatment intensity and duration (CIII) (Table 7). Advanced lines of therapy may increase the risk of clinical HSV/VZV reactivation [89].

Antiviral prophylaxis is most effective during the first year after starting treatment for lymphoma. But reactivations occurred up to 51.3 months from initial immuno-chemotherapy [4], particularly in patients treated with rituximab plus bendamustine and in patients with rituximab or obinutuzumab maintenance [92]. Therefore the duration of antiviral prophylaxis may be extended according to individual risk assessment. SoR and QoE for patients with non-Hodgkin lymphoma and Hodgkin’s disease are summarized in Table 7.

Patients with chronic lymphocytic leukaemia

Patients with chronic lymphocytic leukaemia (CLL) are at increased risk for infection because of compromised immune function, which might be related to the disease itself and/or to the therapy [29, 95]. In a recent retrospective analysis, published as abstract [96], the risk for herpes zoster was comparable in 1210 multiple myeloma patients and 2520 CLL patients (10.5% and 12.9% respectively). In a Swedish nationwide analysis from 1994 to 2013 of inpatient opportunistic infectious complications in CLL patients, herpes zoster was second most common after pneumocystis jirovecii pneumonia. Incidence rates per 1000 patient-years were 2.94 for herpes zoster and 0.8 for HSV reactivations, compared to 0.26 and 0.04 respectively in the age-/sex-/residence-matched control group [97]. Only inpatients were included, thus patients with severe disease, which was also reflected by an early mortality rate of 15% (for herpes zoster) and 13% (for HSV reactivation) [97]. A decreasing rate of herpes zoster cases during time course was possibly linked to increasing use of antiviral pharmacological prophylaxis. However, there are no general recommendations for antiviral pharmacological prophylaxis in patients with CLL [95], probably because the patient population as well as treatment modalities are heterogeneous and the efficacy of antiviral pharmacological prophylaxis has not been evaluated in randomized controlled trials. Thus, for patients with CLL treated with immuno-chemotherapy, our recommendations do not differ from the recommendations for lymphoma patients (BIIuh) (Table 7). Special consideration has to be taken to patients treated with rituximab plus bendamustine or rituximab in combination with fludarabine and cyclophosphamide, as herpesvirus reactivation has been reported frequently and up to 3 years after treatment [98, 99]. Additionally elderly patients, patients with advanced lines of therapy, and patients with a history of VZV or HSV reactivation [100] have been described to be at higher risk and may benefit particularly of pharmacological prophylaxis (Table 7).

Ibrutinib binds covalently Bruton’s tyrosine kinase (BTK) and inhibits its enzymatic activity on development and activity of B-lymphocytes and leads to depression of serum gamma globulins [29, 101]. Concerning herpesvirus reactivations, case reports have demonstrated the potential of fatal disseminated varicella zoster with BTK-inhibition [31, 32, 102]. In contrast, increased opportunistic infections in the ibrutinib-treated cohorts in four phase III trials [103–106] were not seen, while only one trial required antiviral prophylaxis in both arms [103]. Coutre et al. [107] described herpes zoster and oral herpes disease in 5% and 4% respectively during long-term follow-up of 330 patients of the RESONATE and RESONATE-2 trial [105, 108]. We could therefore not find evidence supporting a general recommendation for antiviral prophylaxis in patients treated with BTK inhibitors. Clinicians should be aware that patients may develop atypical infectious complications, including severe reactivations of VZV and HSV. Antiviral prophylaxis might be implemented on the patient’s individual risk, e.g. in case of high age or advanced line of therapy (CIIu) (Table 7).

Intracellular signalling of B-Cell-Lymphoma kinase 2 (BCL2) promotes cellular survival and is highly overexpressed in CLL and other malignancies. Venetoclax is a small molecule binding BCL2 specifically, leading to rapid and deep remissions in CLL patients. Importantly, first line treatment with venetoclax in combination with obinutuzumab lead to grade 3/4 neutropenia in 52.8% and grade 3/4 infections in 17.5% of patients in the pioneering CLL-14 trial [109]. These adverse events did not differ significantly from the control group treated with obinutuzumab plus chlorambucil [109]. Seymour et al. [110] observed comparable adverse events when treating patients with relapsed or refractory CLL with rituximab together with venetoclax. Of note, rates of febrile neutropenia and severe infectious complications were lower in the rituximab plus venetoclax group than in the control group treated with rituximab plus bendamustine [110]. Viral infectious complications have not been reported separately. There was no mandatory antimicrobial prophylaxis in neither of the studies. The existing data about venetoclax are not sufficient to consider a specific risk for VZV or HSV reactivations. In summary, antiviral pharmacological prophylaxis should be administered on the basis of the patient´s individual risk as described above (CIIu) (Table 7).

The use of idelalisib, a phosphatidylinositol-3-kinase-pathway (PI3Kδ)-inhibitor, has been associated with fatal opportunistic infections [111] and relatively frequent reactivations of CMV [112]. For this reason, antiviral pharmacological prophylaxis has been used widely [113] — limiting data on reactivation rates of HSV and VZV [114] — and is recommended (BIII) (Table 7). Moreover, close monitoring for infectious complications is indicated.

Hypogammaglobulinemia is a well-recognized complication associated with CLL. Regarding CLL patients with hypogammaglobulinemia (IgG below 4 g/L) and history of infections, different randomized studies have shown that the prophylactic use of intravenous immunoglobulins decreases the rate of bacterial infections, but not of non-bacterial infections [115]. There is no evidence for a beneficial effect specific on herpesvirus reactivations by polyclonal immunoglobulin substitution.

Patients with multiple myeloma

Reactivation by VZV has been described as frequent infectious complication in patients with multiple myeloma [116, 117] and mainly presents as herpes zoster. It is an important clinical issue in patients with multiple myeloma in all phases of active disease. The proteasome inhibitor bortezomib, in combination with either corticosteroids or other drugs such as melphalan or daratumumab, substantially increases the risk for herpes zoster [62, 116, 117]. Several, mainly retrospective reports indicate that acyclovir prophylaxis significantly reduces the risk of herpes zoster in these patients [118, 119]. The risk of herpes zoster was 13% in the cohort receiving bortezomib and 4% in the control arm in the VISTA trial analysing melphalan-prednisolone with or without bortezomib [62]. The incidence of herpes zoster was reduced to 3% in patients getting bortezomib together with antiviral prophylaxis. Therefore, we strongly recommend acyclovir prophylaxis in patients receiving bortezomib-based treatment regimens (AII) (Table 7). Alternatively valacyclovir might be used [63, 64, 119, 120] (BIIu) (Table 7). More limited data are available on herpes zoster risk and prophylactic strategies in patients receiving other proteasome inhibitors such as carfilzomib or ixazomib [121–123]. Patients who started VZV prophylaxis at study entry had a significantly lower herpes zoster incidence (≤ 1%) in a randomized controlled trial comparing lenalidomide-dexamethasone with ixazomib (versus placebo) in comparison to those not starting VZV prophylaxis (8% and 3% in the ixazomib versus placebo arm, respectively) [121, 123]. Therefore, the increased VZV reactivation risk after proteasome inhibitor-based regimens is rather class-related than associated with selected agents. As a consequence, we also recommend the use of antiviral prophylaxis, mainly with acyclovir, in patients receiving proteasome inhibitors other than bortezomib (AIIu; AIIh) (Table 7). The VZV reactivation risk seems to be rather low (< 5% in the majority of controlled trials) in patients with multiple myeloma receiving other targeted agents (e.g. antibodies, immunomodulatory drugs (IMiDs)), and there are limited data on the use of antiviral prophylaxis in these patients [116, 124, 125]. In summary, we recommend their use only in selected cases, taking in account the patient’s individual VZV disease risk [124] (CIIh; CIIt) (Table 7).

HSV reactivation as stomatitis, if seen, predominantly affects patients treated with autologous HSCT. Recommendations on the management of infections after autologous HSCT — including prophylaxis in multiple myeloma patients — have been published by the AGIHO recently [8]. Limited data exist on the HSV reactivation risk and antiviral prophylaxis in the current era of multiple myeloma management outside the HSCT setting [20, 124, 126–128]. HSV reactivation was reported in 2.7% of patients in an integrated safety profile analysis of single-agent carfilzomib in 526 patients included in four phase II trials [127]. Hereby, antiviral medication was administered concomitantly to 63% of patients while being on study. Taken together, antiviral prophylaxis might be used with the aim to reduce the risk of HSV disease patients with multiple myeloma on an individual case basis (Table 7).

Treatment

Decision for treatment is made after considering the diagnosis on clinical grounds, before (and sometimes without) it is confirmed by virus detection (see Diagnostics). Treatment modalities depend on (a) type and severity of HSV or VZV reactivation, (b) the clinical condition of the patient, and (c) severity of immunosuppression. Oral administration can be used if disease is localized, symptoms are minor, and the immunosuppression can be considered as mild. In these cases, valacyclovir (1000 mg TID) and famciclovir (500 mg BID or TID respectively for herpes genitalis or herpes zoster) may be alternatives to oral acyclovir (400 mg five times per day for localised HSV disease or 800 mg five times per day for herpes zoster), with the limitation that data are deduced from the immunocompromised cohort of patients with human immunodeficiency virus (HIV). Therapy lasts 7 to 10 days in most cases. While on therapy, close clinical monitoring is essential to switch early to intravenous acyclovir when signs of cutaneous dissemination, involvement of the central nervous system, or other organs occur [139]. In patients with severe immunosuppression and thus a high risk for complications, upfront intravenous therapy should be considered [11, 52]. Careful clinical decision making is necessary as early effective therapy is important to reduce complication rate. For intravenous therapy, acyclovir is used with 5 mg/kg body weight TID for HSV reactivation by localized disease [38] and 10 mg/kg body weight TID for disseminated, cerebral or visceral disease of HSV and VZV and for herpes zoster. Disseminated disease as well as cerebral and visceral disease requires treatment for at least 14 days.

At large, treatment recommendations for patients with malignancies are consistent with recommendations and guidelines for the general population [19, 24, 52, 140–143] as trials specific for patients with malignancies have not been performed. It has to be noticed, though, that brivudin is not approved in the immunocompromised patients and most importantly contraindicated in patients treated with 5-fluoruracil or its prodrugs (like capecitabine, tegafur) due to potential lethal hematologic toxicity [25, 38, 144]. Further information about treatment in the immunocompromised patient can also be derived from the AGIHO guideline on infections of the central nervous system in patients with hematological disorders [49] and from the S2-consensus-based guideline, referring to patients after solid organ transplantation or allogeneic HSCT [38].

Conclusion

This guideline updates our recommendations on antiviral prophylaxis in patients with solid tumours and hematological malignancies of 2015 [9]. As it is relevant for some strategies and an often raised question in clinical practice, we included recommendations on diagnostics.

HSV stomatitis (in patients with leukaemia treated with intensive chemotherapy) and herpes zoster (in patients with lymphoma and multiple myeloma) are the most frequent clinical herpesvirus reactivations and affect a considerable number of patients. Prophylaxis with acyclovir (or valacyclovir) has been successfully implemented to reduce these reactivations in different situations, while insufficient data still exist about the effect of antiviral prophylaxis on severe HSV or VZV disease and mortality. Since the previous publication of our guideline, only few prospective randomized studies have been published on prophylaxis of HSV und VZV. But evidence originating from retrospective trials and registries has increased substantially. Recent developments in herpes zoster vaccination strategies have led attention on VZV reactivation rates and clinical sequelae of herpes zoster. Incidence rates from large population groups are now available to better assess relative risk in different groups of patient with malignancies. We therefore update our recommendations from 2015 with regard to different patient groups. Because increasing data show the considerable risk of disease by reactivations of HSV or VZV in specific patient populations, the recommendation was often upgraded. Vaccination strategies will most likely influence the risk of VZV reactivations in the future. Up to now, some data exist on clinical outcomes, mainly in patients with hematologic malignancies, and immunological efficacy (with variable results). Further research is necessary on vaccination efficacy (short- and long-term) in different anticancer treatments.

Abbreviations

AGIHO

Infectious Diseases Working Party

ASCO

American Society of Oncology

ASH

American Society of Hematology

BAL

Bronchoalveolar lavage

BCL2

B-cell-lymphoma kinase 2

BID

Twice daily

BSA

Body surface area

BTK

Bruton’s tyrosine kinase

BW

Bronchial wash

CI

Confidence interval

CMV

Cytomegalovirus

CSF

Cerebrospinal fluid

CT

Computed tomography

DGHO

German Society for Hematology and Medical Oncology

DLBCL

Diffuse large B-cell lymphoma

DNA

Desoxyribonucleic acid

EHA

European Hematology Association (EHA)

EMA

European Medicines Agency

ESCMID

European Society for Clinical Microbiology and Infectious Diseases

ESMO

European Society of Medical Oncology

EBV

Epstein-Barr virus

HHV-6

Human herpesvirus type 6

HIV

Human immunodeficiency virus

HSCT

Hematopoietic stem cell transplantation

HSV-1

Herpes simplex virus type 1

HSV-2

Herpes simplex virus type 2

ISOO

International Society of Oral Oncology

MASCC

Multinational Association of Supportive Care in Cancer

MRI

Magnetic resonance imaging

qPCR

Quantitative polymerase chain reaction

QID

Four times daily

QoE

Quality of evidence

RCT

Randomized controlled trial

RR

Relative risk

SoR

Strength of recommendation

TID

Three times daily

VZV

Varicella zoster virus

Author contribution

Larissa Henze (LH): Study design, data acquisition, data analysis and interpretation, quality control of data and algorithms, manuscript writing.

Christoph Buhl (CB): Data acquisition, data analysis and interpretation, partial manuscript writing.

Michael Sandherr (MS): Study design, data acquisition, data analysis and interpretation, quality control of data and algorithms, manuscript editing.

Oliver A. Cornely (OC): Study concept, study design, data analysis and interpretation, manuscript review.

Werner J. Heinz (WJH): Data acquisition, data analysis and interpretation, manuscript editing.

Yascha Khodamoradi (YK): Data acquisition, data analysis and interpretation.

Til Ramon Kiderlen (TRK): Data acquisition, data analysis and interpretation, manuscript editing.

Philipp Koehler (PK): Study design, data acquisition, data analysis and interpretation, manuscript editing.

Alrun Seidler (AS): Data acquisition, data analysis and interpretation.

Rosanne Sprute (RS): Data acquisition, data analysis and interpretation, manuscript editing.

Martin Schmidt-Hieber (MSH): Study design, data acquisition, data analysis and interpretation, quality control of data and algorithms, partial manuscript writing, manuscript review.

Marie von Lilienfeld-Toal (MvL): Study concept, study design, data analysis and interpretation, manuscript review, supervision.

All authors approved the manuscript to be published.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Declarations

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

Larissa Henze (LH):

Financing of Scientific Research: German Federal Ministry of Research and Education (BMBF).

Outside the submitted work.

Christoph Buhl (CB):

CB has no financial or non-financial interests to disclose.

Michael Sandherr (MS):

Honoraria: Roche, Bristol-Myers Squibb, Novartis.

Oliver A. Cornely (OAC):

OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.

Werner J. Heinz (WJH):

Financing of scientific research: MSD Sharp & Dohme/Merck and Pfizer;

Other Financial Relationships: serves on the speakers’ bureaus of Abbvie, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD Sharp & Dohme, and Pfizer; received travel grants from Abbvie, Alexion, Astellas, Lilly, MSD Sharp & Dohme, Novartis and Pfizer.

Yascha Khodamoradi (YK):

Other Financial Relationships: speaker’s fee and travel grant from GILEAD Science, MSD Sharp & Dome.

Til Ramon Kiderlen (TRK):

Advisory Role: GSK.

Honoraria: Pfizer, GSK.

Financing of scientific research: Pfizer.

Philipp Koehler (PK):

Advisory Role and/or Honoraria: Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., University Hospital, LMU Munich;

Financing of scientific research: German Federal Ministry of Research and Education and the State of North Rhine-Westphalia, Germany;

Non-financial scientific grants: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.

Outside the submitted work.

Alrun Seidler (AS):

AS has no financial or non-financial interests to disclose.

Rosanne Sprute (RS):

RS has no financial or non-financial interests to disclose.

Martin Schmidt-Hieber (MSH):

Advisory Role or Expert Testimony (no personal fee): Celgene GmbH, Amgen, Kite/Pharma Gilead, Sanofi;

Other Financial Relationships: financial support of educational meetings at the Carl-Thiem-Klinikum Cottbus by Janssen-Cilag GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Novartis Pharma Oncology, Pfizer Pharma GmbH, Roche Pharma AG, Vifor Pharma Deutschland

 GmbH, Celgene GmbH.

Marie von Lilienfeld-Toal (MvL):

Advisory Role or Expert Testimony: Celgene, Gilead, Oncopeptides, MSD, 4DPharma, Janssen, Shionogi, Pfizer.

Honoraria: Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Abbvie, AstraZeneca, Pfizer.

Financing of Scientific Research: German Federal Ministry of Research and Education, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, DFG (German Research Foundation), Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides.

Other Financial Relationships (travel grants): Janssen, Celgene.